• About
• Links
• Contact
• Sitemap
• 

Monoclonal Antibodies in Cancer Therapy: Emerging Products and Markets

In 2003, the market for monoclonal antibodies in the treatment of cancer is just short of $2.8 billion and growing at a phenomenal rate. The market is fueled by leading products such as Rituxan and Herceptin; however, other products continue to demand more attention each year. This study reviews market data for the years 2001 to the present and forecasts the market to 2008, including Kalorama’s estimates of the competitive market share in 2008 based on the current pipeline and likely market conditions. Although the primary markets considered in the study are the United States and Europe, estimates of other significant international regions are included.

Products in research and development play a vital part in the continued growth of this market. There are approximately six serious products in Phase III development and another six in Phase II. Other areas of focus for this study include demographics and statistics for cancer, corporate profiles for leading and emerging companies, and product pipeline by development stage. With more than 10 million new cancer cases each year and approximately 50 percent of these in the growing 55 and over population, innovative treatments in cancer will continue to grow at phenomenal rates.

This study represents the second volume in a series of reports on advanced cancer therapeutics. The first volume, The Emerging Cancer Vaccines Market, was published in February 2004; the next will cover other immunomodulators and is due out in July 2004.

Table of Contents

Chapter One
Executive Summary

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

Chapter Two
Introduction and Overview

• History and Growth of the Cancer Treatment Market
  • Monoclonal Antibody Discovery
  • The Naming of Monoclonal Antibodies
• The Role of Biotechnology in Cancer Treatment
• Monoclonal Antibody Use in Cancer Therapy
• Demographics and Statistics

Chapter Three
Current Monoclonal Antibodies for Cancer Treatment

• Description of Cancers with Available Products
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Lymphoma
• Description of Products
  • Avastin (bevacizumab)
  • Bexxar (tositumomab)
  • CamPath (alemtuzumab)
  • Erbitux (cetuximab)
  • Herceptin (trastuzumab)
  • Mylotarg (gemtuzumab ozogamicin)
  • Panorex (edrecolomab)
  • Rituxan (rituximab)
  • Zevalin (ibritumomab tiuxetan)
• Market Size and Growth
• Competitive Analysis

Chapter Four
Emerging Monoclonal Antibodies for Cancer Treatment

• Description of Cancers with New Product Opportunities
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Head and Neck
  • Kidney
  • Leukemia
  • Liver
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Neuroblastoma
  • Ovarian Cancer
  • Pancreas
  • Prostate Cancer
• Cancer Monoclonal Antibody Pipeline
  • Phase III
  • Phase II
  • Phase I
• Market and Product Launch Forecasts
• Potential Competitors and Competitive Forecast

Chapter Five
Issues and Trends

• Insurance and Reimbursement Issues
• Global Issues
• Treatment Obstacles and Costs
• Alliances Acquisitions and Licensing Agreements
• Marketing and Distribution Trends
• Manufacturing Issues
• Immunogenicity
• Diagnostic Applications for Monoclonal Antibodies
• Future Business Strategies

Chapter Six
Total Market Summary

• Total market Size and Forecast
• Competitive Analysis

Chapter Seven
Corporate Profiles: Current Suppliers

• Biogen IDEC, Inc.
• Bristol-Myers Squibb Company/Oncology
• Centocor, Inc.
• Corixa Corporation
• Genentech, Inc.
• GlaxoSmithKline plc
• ILEX Oncology, Inc.
• Imclone Systems, Inc.
• Merck KGaA
• Schering AG/Berlex
• Wyeth

Chapter Eight
Corporate Profiles: Emerging Competitors

• Introduction
• Abbott Laboratories
• Abgenix, Inc.
• AltaRex Medical Corporation
• Amgen, Inc.
• Antisoma plc
• Boehringer Ingelheim GmbH
• Celltech Group plc
• Chugai Pharmaceutical Company, Ltd.
• Coley Pharmaceutical Group
• Crucell N.V.
• Human Genome Sciences, Inc.
• Immuno-Designed Molecules, S.A.
• ImmunoGen, Inc.
• Immunomedics, Inc.
• Intracel Corporation
• Kyowa Hakko Kogyo Company, Ltd.
• Medarex, Inc.
• MedImmune, Inc.
• Millennium Pharmaceuticals, Inc.
• NeoPharm, Inc.
• Peregrine Pharmaceuticals, Inc.
• Protein Design Labs, Inc.
• Roche
• Seattle Genetics, Inc.
• Titan Pharmaceuticals, Inc.
• United Therapeutics Corporation
• Vernalis plc
• Viventia Biotech, Inc.
• Wilex AG
• XOMA, Ltd.
• YM Biosciences, Inc.

Appendix A: Company Names and Addresses
Appendix B: Regulatory Authorities and Organizations

List of Exhibits

Chapter One: Executive Summary

• Table 1-1: Worldwide Market for Monoclonal Antibody Products in Cancer Therapy 2001-2008
• Figure 1-1: Worldwide Market for Monoclonal Antibody Products in Cancer Therapy 2001-2008

Chapter Two: Introduction and Overview

• Table 2-1: Monoclonal Antibody Source Identifiers
• Table 2-2: Monoclonal Antibody Disease or Target Class Identifiers
• Table 2-3: Examples of Approved Monoclonal Antibodies by Name Origin
• Table 2-4: Estimated and Projected World Cancer Incidence by Common Type of Cancer, 2003 and 2020
• Figure 2-1: Estimated and Projected World Cancer Incidence by Common Type of Cancer, 2003 and 2020
• Table 2-5: Estimated and Projected World Cancer Mortality by Common Type of Cancer, 2003 and 2020
• Figure 2-2: Estimated and Projected World Cancer Mortality by Common Type of Cancer, 2003 and 2020
• Table 2-6: World Population by Selected Geographical Region, 2003-2050
• Figure 2-3: World Population by Selected Geographical Region, 2003-2050
• Table 2-7: Estimated World Population by Age and Geographical Region, 2003
• Figure 2-4: Estimated World Population by Age and Geographical Region, 2003
• Table 2-8: Life Expectancy at Birth by Selected Countries, 2000
• Table 2-9: United States Life Expectancy at Birth, 1990-2000, and Projections, 2005-2010
• Figure 2-5: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2000
• Figure 2-6: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2000

Chapter Three: Current Monoclonal Antibodies for Cancer Treatment

• Table 3-1: Types of Leukemia, Incidence, Characteristics, Manifestations
• Table 3-2: Classification of Non-Hodgkin’s Lymphomas
• Table 3-3: Estimated World and U.S. Incidence and Mortality of Cancers with Current Monoclonal Antibody Treatments (in thousands)
• Figure 3-1: Cancer Monoclonal Antibodies: Estimated World Incidence and Mortality of Cancers with Current Monoclonal Antibody Treatment (thousands)
• Figure 3-2: Cancer Monoclonal Antibodies: Estimated U.S. Incidence and Mortality of Cancers with Current Monoclonal Antibody Treatment (thousands)
• Table 3-4: The Market for Currently Available Monoclonal Antibody Products for Cancer 2001-2008
• Figure 3-3: Current Cancer Monoclonal Antibody Market, 2001-2008
• Table 3-5: The Market for Currently Available Monoclonal Antibody Products for Cancer Revenues by Cancer Type, 2003
• Figure 3-4: The Market for Currently Available Monoclonal Antibody Products for Cancer Market Share by Cancer Type 2003
• Table 3-6: The Market for Currently Available Monoclonal Antibody Products for Cancer Revenues and Market Shares by Leading Supplier 2003
• Figure 3-5: The Market for Currently Available Monoclonal Antibody Products for Cancer Market Shares by Leading Supplier 2003
• Table 3-7: The Market for Currently Available Monoclonal Antibody Products for Cancer Estimated Revenues and Market Shares by Leading Supplier 2004
• Figure 3-6: The Market for Currently Available Monoclonal Antibody Products for Cancer Estimated Market Shares by Leading Supplier 2004

Chapter Four: Emerging Monoclonal Antibodies for Cancer Treatment

• Table 4-1: Types of Leukemia, Incidence, Onset, and Manifestations
• Table 4-2: Types of Primary Lung Cancer, Risk Factors
• Table 4-3: Classification of Non-Hodgkin’s Lymphomas
• Table 4-4: Malignant Conditions of The Skin
• Table 4-5: Estimated World Incidence and Mortality of Selected Cancers (in thousands)
• Figure 4-1: Estimated World Incidence and Mortality of Cancers with Emerging Monoclonal Antibody Therapies
• Figure 4-2: Estimated U.S. Incidence and Mortality of Cancers with Emerging Monoclonal Antibody Therpies
• Table 4-6: Cancer Monoclonal Antibodies in the Development Pipeline
• Table 4-7: Emerging Cancer Monoclonal Antibody Market 2004-2008
• Figure 4-3: Emerging Cancer Monoclonal Antibody Market 2004-2008
• Table 4-8: Emerging Cancer Monoclonal Antibody Market by Cancer Type 2004-2008
• Compound Annual Growth Rate
• Figure 4-4: Emerging Cancer Monoclonal Antibody Market by Cancer Type 2004-2008
• Figure 4-5: Emerging Cancer Monoclonal Antibody Market Distribution of Revenues by Cancer Type 2004-2008
• Table 4-9: Emerging Monoclonal Antibody Market Projected Market Shares by Leading Suppliers 2008
• Figure 4-6: Emerging Monoclonal Antibodies in Cancer Projected Market Share by Leading Supplier 2008
• Table 4-10: Projected 2008 Revenues by Competitor and Cancer Type

Chapter Five: Issues and Trends

• Table 5-1: Competitive Strategies of Biotech Companies

Chapter Six: Total Market Summary

• Table 6-1: Total Market for Monoclonal Antibody Therapeutics in Cancer 2001-2008
• Figure 6-1: Total Market for Monoclonal Antibody Therapeutics in Cancer 2001-2008
• Table 6-2: World Market for Monoclonal Antibody Therapies in Cancer by Product Availability 2001-2008
• Figure 6-2: World Market for Monoclonal Antibody Therapies in Cancer by Product Availability 2001-2008
• Figure 6-3: Distribution by Cancer Type of Current and Developmental Monoclonal Antibody Products for Cancer, 2003
• Figure 6-4: Number of Current and Developmental Monoclonal Antibody Products for Cancer by Cancer Type and Development Phase
• Figure 6-5: Distribution by Development Phase of Monoclonal Antibody Products for Cancer

Other users found this report page using the following search terms: antibodies antibody monoclonal cancer antibodies treatment antibody therapy market products 2008 emerging

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.